146 related articles for article (PubMed ID: 38320748)
1. Refractory lupus hepatitis successfully treated with telitacicept who failed to belimumab: A case report and literature review.
Fan Q; Ji H; Liu Y; Jia C; Zou L; Yang H
Lupus; 2024 Apr; 33(4):414-419. PubMed ID: 38320748
[No Abstract] [Full Text] [Related]
2. Safety and efficacy of telitacicept in refractory systemic lupus erythematosus patients who failed treatment with belimumab : A case series.
Fan Q; Yang H; Liu Y
Z Rheumatol; 2024 Jun; 83(5):387-392. PubMed ID: 38157053
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of Telitacicept in a systemic lupus erythematosus patient with suboptimal response to Belimumab: A case report.
Huang L; Qian G; Zhang H; Li Q; Chen L; Tang X; Zhao H
Lupus; 2024 Feb; 33(2):172-175. PubMed ID: 38081170
[TBL] [Abstract][Full Text] [Related]
4. Telitacicept for Recalcitrant Cutaneous Manifestations of Systemic Lupus Erythematosus: A Case Report and Review of the Literature.
Ma X; Fu X; Cui B; Lin H
Tohoku J Exp Med; 2022 Oct; 258(3):219-223. PubMed ID: 36047131
[TBL] [Abstract][Full Text] [Related]
5. Telitacicept, a novel humanized, recombinant TACI-Fc fusion protein, for the treatment of systemic lupus erythematosus.
Fan Y; Gao D; Zhang Z
Drugs Today (Barc); 2022 Jan; 58(1):23-32. PubMed ID: 35107091
[TBL] [Abstract][Full Text] [Related]
6. A patient with refractory proliferative lupus nephritis treated with telitacicept: A case report.
Chen JW; Zhan JY; Liang SP; Wang XD; Lin CS; Xu Q
Int J Rheum Dis; 2023 Jul; 26(7):1417-1421. PubMed ID: 37218552
[TBL] [Abstract][Full Text] [Related]
7. B-cell targeted therapies in systemic lupus erythematosus: successes and challenges.
Harvey PR; Gordon C
BioDrugs; 2013 Apr; 27(2):85-95. PubMed ID: 23456653
[TBL] [Abstract][Full Text] [Related]
8. The efficacy of rituximab plus belimumab or telitacicept in refractory lupus nephritis.
Chen Y; Shi N; Lei X; Ren P; Lan L; Chen L; Wang Y; Xu Y; Lin Y; Chen J; Han F
Rheumatology (Oxford); 2023 Dec; ():. PubMed ID: 38145455
[TBL] [Abstract][Full Text] [Related]
9. Telitacicept as a BLyS/APRIL dual inhibitor for autoimmune disease.
Shi F; Xue R; Zhou X; Shen P; Wang S; Yang Y
Immunopharmacol Immunotoxicol; 2021 Dec; 43(6):666-673. PubMed ID: 34519594
[TBL] [Abstract][Full Text] [Related]
10. Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trial.
Wu D; Li J; Xu D; Merrill JT; van Vollenhoven RF; Liu Y; Hu J; Li Y; Li F; Huang C; Wang G; Li X; Zhao J; Zhao D; Huang C; Liu H; Wei W; Shi G; Lu F; Zuo X; Bi L; Li Z; Wang X; Zhang M; Tie N; Li J; Mo H; Fang J; Bao C; Zhang F
Ann Rheum Dis; 2024 Mar; 83(4):475-487. PubMed ID: 38129117
[TBL] [Abstract][Full Text] [Related]
11. Belimumab for the treatment of systemic lupus erythematosus.
Jordan N; D'Cruz DP
Expert Rev Clin Immunol; 2015 Feb; 11(2):195-204. PubMed ID: 25543845
[TBL] [Abstract][Full Text] [Related]
12. Telitacicept: First Approval.
Dhillon S
Drugs; 2021 Sep; 81(14):1671-1675. PubMed ID: 34463932
[TBL] [Abstract][Full Text] [Related]
13. Efficacy, pharmacokinetic and pharmacodynamic profile of belimumab for systemic lupus erythematosus.
Jordan NP; D'Cruz DP
Expert Opin Drug Metab Toxicol; 2015; 11(10):1635-45. PubMed ID: 26327145
[TBL] [Abstract][Full Text] [Related]
14. Belimumab for the treatment of pediatric patients with lupus nephritis.
Stohl W; Kwok A
Expert Opin Biol Ther; 2023 Mar; 23(3):243-251. PubMed ID: 36750049
[TBL] [Abstract][Full Text] [Related]
15. Successful sequential therapy with rituximab and belimumab in patients with active systemic lupus erythematosus: a case series.
Gualtierotti R; Borghi MO; Gerosa M; Schioppo T; Larghi P; Geginat J; Meroni PL
Clin Exp Rheumatol; 2018; 36(4):643-647. PubMed ID: 29533753
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of telitacicept in refractory childhood-onset systemic lupus erythematosus: A self-controlled before-after trial.
Sun L; Shen Q; Gong Y; Li Y; Lv Q; Liu H; Zhao F; Yu H; Qiu L; Li X; He X; Chen Y; Xu Z; Xu H
Lupus; 2022 Jul; 31(8):998-1006. PubMed ID: 35499216
[TBL] [Abstract][Full Text] [Related]
17. The efficacy and safety of telitacicept for the treatment of systemic lupus erythematosus: a real life observational study.
Chen R; Fu R; Lin Z; Huang C; Huang W
Lupus; 2023 Jan; 32(1):94-100. PubMed ID: 36416639
[TBL] [Abstract][Full Text] [Related]
18. Elevated BLyS levels in patients with systemic lupus erythematosus: Associated factors and responses to belimumab.
Roth DA; Thompson A; Tang Y; Hammer AE; Molta CT; Gordon D
Lupus; 2016 Apr; 25(4):346-54. PubMed ID: 26385220
[TBL] [Abstract][Full Text] [Related]
19. Belimumab for the treatment of recalcitrant cutaneous lupus.
Vashisht P; Borghoff K; O'Dell JR; Hearth-Holmes M
Lupus; 2017 Jul; 26(8):857-864. PubMed ID: 28121495
[TBL] [Abstract][Full Text] [Related]
20. Clinical efficacy of belimumab in patients with systemic lupus erythematosus and headache. A report of two cases.
Kodera T; Tsutsumi T; Oka Y; Takeda T; Shirota Y; Kameoka J
Mod Rheumatol Case Rep; 2022 Jan; 6(1):25-28. PubMed ID: 34505625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
